CDG UPDATES
CDG UPDATES
发布者:CDG Capital 时间:2020年12月31日
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province,completed a $515 million IPO on the Hong Kong exchange in the largest biotech IPO of the year. Founded in 2008, RemeGen is developing a portfolio of ten novel mAbs, fusion proteins, antibody-drug conjugates (ADCs) and bifunctional antibodies. Two of its candidates are under NDA review in China: telitacicept for autoimmune diseases (systemic lupus erythematosus) and disitamab vedotin for HER2 cancers. The company's shares have traded 34% higher since the IPO, giving RemeGen a market capitalization of $4.3 billion.
WeChat Official Account
Suite 4704, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong
Tel:852 3520 0635
Email: cdg@cdginv.com
©️ 2020 All Rights Reserved 晨岭资本有限公司 版权所有 粤ICP备2020113789号